Abstract
Primary central nervous system lymphoma is a stage 1E non-Hodgkin's lymphoma confined to the nervous system. It is seen in immunocompetent and immunodeficient populations, the latter group associated with the Epstein-Barr virus. Primary central nervous system lymphoma can affect the brain, leptomeninges, spinal cord or eyes. The institution of high-dose methotrexate-based regimens and whole-brain radiation therapy has significantly increased survival, but neurotoxicity is high in patients over 60 years of age. Despite these advances, 50% of patients initially treated will relapse. Recent investigations include the use of rituximab (immunotherapy) and stem-cell transplantation, as well as regimens without whole-brain radiation therapy in the elderly. The optimal treatment regimen is yet to been determined.
Original language | English (US) |
---|---|
Pages (from-to) | S63-S70 |
Journal | Expert Review of Neurotherapeutics |
Volume | 5 |
Issue number | 6 SUPPL. |
DOIs | |
State | Published - Nov 2005 |
Keywords
- Methotrexate
- Primary central nervous system lymphoma
- Primary intraocular lymphoma
- Whole-brain radiation therapy
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
- Pharmacology (medical)